The veno-occlusive disease of the liver

Haematologica

Volumn 82, Issue 6, 1997, Pages 718-725

  Baron, Frédéric ^a   Deprez, Manuel ^a   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anticoagulation; Liver complications; Stem cell transplantation; Veno occlusive disease

Indexed keywords

HEPARIN; PENTOXIFYLLINE; PROSTAGLANDIN E1; URSODEOXYCHOLIC ACID;

ANTICOAGULATION; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; LIVER VENOOCCLUSIVE DISEASE; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; RISK FACTOR;

BONE MARROW TRANSPLANTATION; DIAGNOSIS, DIFFERENTIAL; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; RISK FACTORS;

EID: 0031454109     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Shulman HM, McDonald GB, Matthews DE, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79:1178-91.
2. Wilmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to Senecio poisoning. Lancet 1920; 2:848-9.
3. Lucarelli G, Galimbert M, Delfini C, et al. Marrow transplantation for thalassaemia following busulfan and cyclophosphamide. Lancet 1985; i:1355-7.
4. Essel JH, Thompson JM, Harman GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for traft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79:2784-8.
5. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4:116-22.
6. McDonald GB, Hinds M, Fisher L, Schoch HG. Liver toxicity following cytoreductive therapy for marrow transplantation: risk factors, incidence, and outcome [abstract]. Hepatology 1991; 14:162A.
7. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transpl 1992; 10:197-214.
8. Jones RJ, Lee KSK, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44:778-83.
9. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118:255-67.
10. McDonald GB, Shulman HM, Wolford JL, Spencer GD. Liver disease after human marrow transplantation. Semin Liver Dis 1987; 7:210-29.
11. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005-20.
12. Carreras E, Grañena A, Rozman C. Hepatic veno-occlusive disease after bone marrow transplant. Blood Rev 1993; 7:43-51.
13. Faioni EM, Krachmalnicoff A, Bearman SI, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81:3458-62.
14. Scrobohachi MI, Drouet L, Monemmashi A, et al. Liver veno-occlusive disease after bone marrow transplantation: changes in coagulation parameters and endothelial markers. Thromb Res 1991; 63:509-19.
15. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75:1011-6.
16. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78:1205-11.
17. Rappaport AM, Knoblauch M, Zelin S, Summerall J, Bras G. Experimental hepatic veno-occlusive disease. In vivo microcirculatory study. Adv Microcirc 1969; 2:69-79.
18. Ayash LJ, Hunt M, Antmart K, et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation for solid tumors and lymphomas. J Clin Oncol 1990; 8:1699-706.
19. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83:1998-2004.
20. Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transpl 1994; 14:369-72.
21. Ringden O, Ruutu T, Remberger M, et al. A randomised trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation group. Blood 1994; 83:2723-30.
22. Devergie A, Biaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French society of bone marrow graft (SFCM). Blood 1995; 85:2263-8.
23. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973-9.
24. Deeg HJ, Sullivan KM, Buckner CD, et al. Marrow transplantation for nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transpl 1986; 1:151-7.
25. Valls A, Granena A, Carreras E, Ferrer E, Algara M. Total body irradiation in bone marrow transplantation: fractionated vs single dose. Acute toxicity and preliminary results. Bull Cancer 1989; 76:797-804.
26. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25:55-61.
27. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20(Suppl 4):18-25.
28. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transpl 1994; 14:759-65.
29. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transpl 1996; 17:225-30.
30. Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transpl 1996; 17:341-6.
31. Zager RA, O'Quigley J, Zager RN, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. AmJ Kidney Dis 1989; 13:210-6.
32. Wingard JR, Mellits ED, Jones RJ, et al. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients. Bone Marrow Transpl 1989; 4:685-9.
33. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 9:1729-36.
34. Carreras E, Grañena A, Navasa M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66:77-80.
35. Wolford JL, McDonald GB. A problem-oriented approach to intestinal and liver disease after marrow transplantation. J Clin Gastroenterol 1988; 20:419-33.
36. Goodrich JM, Reed EC, Mori M, et al. Clinical features and risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164:731-40.
37. Lewis JH, Patel HR, Zimmerman HJ. The spectrum of hepatic candidiasis. Hepatology 1982; 2:479-87.
38. Carreras E, Granena A, Navasa M, et al. Transjugular liver biopsy in BMT. Bone Marrow Transpl 1993; 11:21-6.
39. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59:1015-22.
40. Iqbal M, Creger RJ, Fox RM, et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management. Bone Marrow Transpl 1996; 17:655-62.
41. Shulman HM, McDonald GB, Matthews DE, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79:1178-91.
42. Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986; 90:446-54.
43. Lee RG. Vascular disorders. In: Lee RG, ed. Diagnostic liver pathology, Saint Louis: Mosby year book INC; 1994. p. 329-31.
44. Shulman HM, Gown AM, Nugent DJ. Hepatic venocclusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127:549-58.
45. Bradbury P, Gordon KC. Connective tissue and stains. In: Bancroft JD, Stevens A, eds. Theory and practice of histological techniques, III. New York: Churchill Livingstone; 1990. p. 119-42.
46. Hommeyer SC, Teefey SA, Jacobson AF, et al. Venocclusive disease of the liver: prospective study of US evaluation. Radiology 1992; 184:683-6.
47. Heikinheimo M, Halila R, Fasth A. Serum procollagen type III is an early sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994; 83:3036-40.
48. Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transpl 1993; 11:471-2.
49. Salat B, Holler E, Kolb HJ, at al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89:2184-8.
50. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomised trial. Blood 1992; 79:2834-40.
51. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61:1067-71.
52. Gluckman K, Jolivet I, Scrobohaci ML, et al. Use of prostaglandin El for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74:277-81.
53. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin El for the prevention of hepatic venocclusive disease after bone marrow transplantatton. Br J Haematol 1993; 84:724-30.
54. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomised trial. Blood 1993; 82:732-6.
55. Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transpl 1992; 10:367-72.
56. Essell J, Schroeder M, Thompson J, Harman G, Halvorson R, Callander N. A randomised double-blind trial of prophylactic ursodeoxycholic acid vs placebo to prevent venocclusive disease of the liver in patients undergoing allogeneic bone marrow transplantation [abstract]. Blood 1994; 84 (Suppl 1):250a.
57. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89:1501-6.
58. Richardson P, Krishnan A, Wheeler C, et al. The use of defibrotide in BMT-associated veno-occlusive disease [abstract]. Blood 1995; 86(Suppl 1):221a.
59. Murray JA, LaBrecque DR, Gingrich RD, Pringle KC, Mitros FA. Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with side-to-side portocaval shunt. Gastroenterology 1987; 92:1073-7.
60. de la Rubia J, Carrai A, Montes H, Urquijo JJ, Sanz GF, Sanz MA. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS). Haematologica 1996; 81:536-9.
61. Smith FO, Johnson MS, Scherer LR, et al. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transpl 1996; 18:643-6.
62. Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588-91.
63. Rapoport AP, Doyle HR, Starzl T, et al. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transpl 1991; 8:421-4.
64. Dowlati A, Honore P, Damas P, et al. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. Transplantation 1995; 60:106-9.